Adjuvant chemotherapy in early-stage breast cancer: what, when, and for whom?

Surgical Oncology Clinics of North America
Catherine M Kelly, Gabriel N Hortobagyi

Abstract

Adjuvant chemotherapy is effective in reducing the risk of recurrence and death from breast cancer. Tumor stage and biologic characteristics are important when making decisions about who should receive chemotherapy and what chemotherapy to give. The results of ongoing clinical trials will establish whether more precise determination of prognosis and populations most likely and least likely to benefit from specific therapies can improve the efficacy and reduce the toxicity of systemic treatments. As individual tumors are molecularly characterized and molecularly targeted therapies are clinically validated, "personalized" adjuvant therapy will become a reality in the not too distant future.

References

Feb 19, 1976·The New England Journal of Medicine·G BonadonnaU Veronesi
Feb 23, 1989·The New England Journal of Medicine·E G MansourG Falkson
Feb 15, 1995·JAMA : the Journal of the American Medical Association·G BonadonnaP Valagussa
Dec 9, 1997·Journal of the National Cancer Institute·B FisherR G Margolese
Mar 28, 1998·Breast Cancer Research and Treatment·K Rygaard, M Spang-Thomsen
Aug 30, 2000·Nature·C M PerouD Botstein
Feb 2, 2002·Nature·Laura J van 't VeerStephen H Friend
Mar 4, 2003·Breast Cancer Research and Treatment·Kenneth R HessGabriel N Hortobagyi
Mar 15, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·I Craig HendersonLarry Norton
May 21, 2003·Breast Cancer Research and Treatment·Tero A H Järvinen, Edison T Liu
Aug 15, 2003·Proceedings of the National Academy of Sciences of the United States of America·Christos SotiriouEdison T Liu
Oct 2, 2003·Journal of the National Cancer Institute·William D FoulkesLars A Akslen
Sep 8, 2004·Lancet·Bernard FisherUNKNOWN National Surgical Adjuvant Breast and Bowel Project randomised clinical trials
Dec 14, 2004·The New England Journal of Medicine·Soonmyung PaikNorman Wolmark
Apr 20, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ivo A OlivottoKaren A Gelmon
May 18, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eleftherios P MamounasNorman Wolmark
May 26, 2005·Proceedings of the National Academy of Sciences of the United States of America·Roman RouzierLajos Pusztai
Jun 3, 2005·The New England Journal of Medicine·Miguel MartinUNKNOWN Breast Cancer International Research Group 001 Investigators
Aug 10, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Marjorie C GreenGabriel N Hortobagyi
Aug 18, 2005·Journal of the National Cancer Institute·Yu ShenDonald A Berry
Aug 24, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Roman RouzierLajos Pusztai
Sep 8, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Luca GianniSteven Shak
Oct 21, 2005·The New England Journal of Medicine·Martine J Piccart-GebhartUNKNOWN Herceptin Adjuvant (HERA) Trial Study Team
Oct 21, 2005·The New England Journal of Medicine·Edward H RomondNorman Wolmark
Nov 1, 2005·The Lancet Oncology·Maureen TrudeauShailendra Verma
Dec 8, 2005·Journal of the National Cancer Institute·Marco VenturiniPaolo Bruzzi
Feb 24, 2006·The New England Journal of Medicine·Heikki JoensuuUNKNOWN FinHer Study Investigators
Mar 3, 2006·Psycho-oncology·Laura A SiminoffPeter M Ravdin
Mar 7, 2006·Nature Reviews. Drug Discovery·Gergely SzakácsMichael M Gottesman
Apr 12, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Harry D BearNorman Wolmark
Apr 13, 2006·JAMA : the Journal of the American Medical Association·Donald A BerryEric P Winer
May 19, 2006·The New England Journal of Medicine·Kathleen I PritchardUNKNOWN National Cancer Institute of Canada Clinical Trials Group

❮ Previous
Next ❯

Citations

Jul 18, 2012·Asian Pacific Journal of Cancer Prevention : APJCP·Im-Ryung KimJung-Hyun Yang
May 25, 2012·Journal of the National Cancer Institute. Monographs·Jane ZapkaKatherine Sterba
Feb 15, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Catherine M KellyAman U Buzdar
Sep 23, 2014·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Derya Hopanci BicakliRuchan Uslu
Jun 2, 2016·American Society of Clinical Oncology Educational Book·Domen Ribnikar, Fatima Cardoso

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Invasive Carcinoma

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

Breast Invasive Carcinoma (Keystone)

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Breast Cancer: BRCA1 & BRCA2

Mutations involving BRCA1, found on chromosome 17, and BRCA2, found on chromosome 13, increase the risk for specific cancers, such as breast cancer. Discover the last research on breast cancer BRCA1 and BRCA2 here.

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

© 2021 Meta ULC. All rights reserved